Global Cancer Vaccine Partnering 2010-2015: Deal trends, players, financials and forecasts

336 pages report Published in
Pharmaceuticals
Publisher: Current Partnering

The Global Cancer Vaccine Partnering 2010-2015 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in cancer vaccine partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer vaccine partnering contract documents
  • Top cancer vaccine deals by value

The Global Cancer Vaccine Partnering 2010-2015 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 150 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

This report provides details of the latest cancer vaccine agreements announced in the healthcare sectors covering the following diagnostics types including adjuvant.

  • Attenuated vaccine
  • Subunit vaccine
  • Toxoid vaccine
  • Conjugate vaccine
  • Inactivated vaccine
  • DNA vaccine
  • Recombinant vector vaccine

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive cancer vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering cancer vaccine partnering deals.

The report presents average financial deal terms values for cancer vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the cancer vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 150 online deals records of actual cancer vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Report scope

Global Cancer Vaccine Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

Global Cancer Vaccine Partnering 2010-2015 includes:

  • Trends in cancer vaccine dealmaking in the biopharma industry since 2010
  • Analysis of cancer vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 150 cancer vaccine deal records
  • The leading cancer vaccine deals by value since 2010

In Global Cancer Vaccine Partnering 2010-2015 , the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Vaccine Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 160 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Cancer Vaccine Partnering 2010-2015 provides the reader with the following key benefits:

  • In-depth understanding of cancer vaccine deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Acces to the structure of cancer vaccine agreements with numerous real life case studies
  • Comprehensive access to over 150 actual cancer vaccine deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of cancer vaccine deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading cancer vaccine deals by value since 2010
  • Identify the most active cancer vaccine dealmakers since 2010
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer vaccine dealmaking
2.1. Introduction
2.2. Cancer vaccine partnering over the years
2.3. Cancer vaccine partnering by deal type
2.4. Cancer vaccine partnering by industry sector
2.5. Cancer vaccine partnering by stage of development
2.6. Cancer vaccine partnering by cancer indication

Chapter 3 - Average financial deal terms for cancer vaccine partnering
3.1. Introduction
3.2. Disclosed financials terms for cancer vaccine partnering
3.2.1.Cancer vaccine partnering headline values
3.2.2. Cancer vaccine deal upfront payments
3.2.3. Cancer vaccine deal milestone payments
3.2.4. Cancer vaccine royalty rates

Chapter 4 - Leading cancer vaccine deals
4.1. Introduction
4.2. Most active in cancer vaccine partnering
4.3. Top cancer vaccine deals by value
4.4. Big pharma cancer vaccine dealmaking activity

Chapter 5 - Cancer vaccine dealmaking contracts directory
5.1. Introduction
5.2. Cancer vaccine deals by company A-Z
5.3. Cancer vaccine deals by stage of development
5.4. Cancer vaccine deals by deal type

Chapter 6 - Cancer vaccine dealmaking by specific therapy type
6.1. Introduction
6.2. Deals by oncology type

Chapter 7 - Cancer vaccine dealmaking by specific technology type
7.1. Introduction
7.2. Deals by adjuvant and vaccines type

Chapter 8 - Future trends and companies in cancer vaccine deal making
8.1. Introduction
8.2. Emerging companies to watch in 2015
8.3 Emerging companies dealmaking in 2010-2015
8.4. Emerging company financings in 2010-2015
8.5 Conclusion

Appendices
Introduction
Appendix 1 - Directory of cancer vaccine deals by company A-Z 2010-2015
Appendix 2 - Directory of cancer vaccine deals by stage of development 2010-2015
Appendix 3 - Directory of cancer vaccine deals by deal type 2010-2015

Chapter 9 -Partnering resource center
9.1. Online partnering
9.2. Partnering events
9.3. Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Table of Figures

Figure 1: Cancer vaccine partnering since 2010
Figure 2: Cancer vaccine partnering by deal type since 2010
Figure 3: Cancer vaccine partnering by industry sector since 2010
Figure 4: Cancer vaccine partnering by stage of development since 2010
Figure 5: Cancer vaccine partnering by oncology target since 2010
Figure 6: Cancer vaccine deals with a headline value - by stage of development
Figure 7: Cancer vaccine deals with upfront payment values - by stage of development
Figure 8: Cancer vaccine deals with milestone payment - by stage of development
Figure 9: Cancer vaccine deals with royalty rates
Figure 10: Active cancer vaccine dealmaking activity- 2010 to 2015
Figure 11: Top cancer vaccine by value since 2010
Figure 12: Big pharma - top 50 - Cancer vaccine deals 2010 to 2015
Figure 13: Big pharma cancer vaccine deal frequency - 2010 to 2015
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events

Related Reports

  • Wound Healing Partnering 2010-2015
    "Delivery of this report will take 1-3 days after purchase." The Wound Healing Partnering 2010-2015 report provides understanding and access to the wound healing partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in wound healing partnering deals Top wound healing deals by value Deals listed by company A-Z, industry sector, stage of development, technology type The Wound Healing Partnering 2010-2015 provides understanding and access to t...
  • Discovery Stage Partnering Terms and Agreements
    The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or com...
  • Infectious Vaccines Partnering Terms and Agreements
    The Infectious Vaccines Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. This re...
  • PharmaPoint: Prophylactic Human PapillomaVirus Vaccines – Current and Future Players
    GlobalData has released its pharma report, "PharmaPoint: Prophylactic Human PapillomaVirus Vaccines Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prophylactic Human Papillomavirus Vaccines Market. The report identifies and analyses the key companies shaping and driving the global Prophylactic Human Papillomavirus Vaccines market. The report provides insight into the competitive Prophylactic Human...
  • Global Biomarker Partnering 2010-2015: Deal trends, players, financials and forecasts
    The Global Biomarker Partnering 2010-2015: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in biomarker partnering deals Biomarker partnering agreement structure Biomarker partnering contract documents Top biomarker deals by value Most active biomarker dealmakers The Global Biomarker Partnering 2010-201...